{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:39:01Z","timestamp":1792539541385,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HIV remains highly prevalent in Uganda, where CD4 T-cell counts are central to identifying and managing Advanced HIV Disease (AHD). Instrument-based point-of-care (POC) CD4 platforms face cost and operational constraints in resource-limited settings. The VISITECT CD4 lateral flow immunoassay (LFA) offers a non-instrument-based alternative, but its diagnostic validity against the Pima Analyzer had not been evaluated in Uganda.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare diagnostic validity of the VISITECT CD4 LFA against the Pima Analyzer at the 200 cells\/\u00b5L AHD threshold and explore factors influencing performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comparative cross-sectional study was conducted between June and August 2023 at three Kampala health centres. Venous blood from 351 HIV-positive adults was tested simultaneously on both platforms. Sensitivity, specificity, PPV, NPV, and likelihood ratios were calculated with 95% CIs using the Pima Analyzer\u2014a point-of-care, not gold-standard, platform\u2014as reference; estimates reflect relative, not absolute, performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most participants were female (68.11%), median age 31 years; mean CD4 count was 482 cells\/\u00b5L (\u00b1\u2009283.9) and AHD prevalence 22.79%. VISITECT CD4 LFA showed sensitivity of 86.25% (95% CI: 76.73\u201392.93), specificity of 90.41% (95% CI: 86.26\u201393.64), PPV of 72.63% (95% CI: 64.57\u201379.44), NPV of 95.70% (95% CI: 92.78\u201397.48), and inter-rater agreement \u03ba\u2009=\u20090.957. No assessed factor significantly modified performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The VISITECT CD4 LFA performed reliably as an AHD screening tool relative to the Pima Analyzer in resource-limited settings, particularly where instrument-based platforms are unavailable. It should complement, not replace, confirmatory testing; improvements in sensitivity and PPV remain warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-14021-y","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:55:17Z","timestamp":1784890517000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the diagnostic validity of the HIV VISITECT CD4 point-of-care rapid diagnostic test in Uganda"],"prefix":"10.1186","volume":"26","author":[{"given":"Oliver","family":"Nakamaanya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Bagaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy","family":"Ssengooba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Thokerunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Zamarano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"14021_CR1","doi-asserted-by":"crossref","unstructured":"Dwyer-Lindgren L, Cork MA, Sligar A, Steuben KM, Wilson KF, Provost NR, et al. Mapping HIV prevalence in sub-Saharan Africa between 2000 and 2017. Nature. 2019.","DOI":"10.1038\/s41586-019-1200-9"},{"key":"14021_CR2","unstructured":"UNAIDS. In Danger: UNAIDS Global AIDS Update 2022. Geneva: UNAIDS. 2022. Available from: https:\/\/www.unaids.org\/en\/resources\/documents\/2022\/in-danger-global-aids-update"},{"key":"14021_CR3","unstructured":"UPHIA. Uganda Population-based HIV Impact Assessment (UPHIA 2020\u2013. 2021). Kampala; 2021. Available from: https:\/\/phia.icap.columbia.edu\/wp-content\/uploads\/2022\/08\/UPHIA-Summary-Sheet-2020.pdf"},{"key":"14021_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/COH.0000000000000348","volume":"12","author":"N Ford","year":"2017","unstructured":"Ford N, Meintjes G, Vitoria M, Greene G, Chiller T. The evolving role of CD4 cell counts in HIV care. Curr Opin HIV AIDS. 2017;12:123\u20138.","journal-title":"Curr Opin HIV AIDS"},{"key":"14021_CR5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12879-020-04972-1","volume":"20","author":"ZG Dessie","year":"2020","unstructured":"Dessie ZG, Zewotir T, Mwambi H, North D. Modelling of viral load dynamics and CD4 cell count progression in an antiretroviral naive cohort: using a joint linear mixed and multistate Markov model. BMC Infect Dis. 2020;20:246.","journal-title":"BMC Infect Dis"},{"key":"14021_CR6","unstructured":"World Health Organization. Consolidated guidelines on person-centred HIV patient monitoring and case surveillance. Geneva: WHO. 2017. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/255702"},{"key":"14021_CR7","unstructured":"CDC\/NIH. Baseline Evaluation. HIV clinical guidelines: adult and adolescent ARV. 2022. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/baseline-evaluation"},{"key":"14021_CR8","unstructured":"NIH. Lab tests and results. HIV.gov. 2022. Available from: https:\/\/www.hiv.gov\/hiv-basics\/staying-in-hiv-care\/provider-visits-and-lab-test\/lab-tests-and-results"},{"key":"14021_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12981-020-00296-x","volume":"17","author":"AT Boyd","year":"2020","unstructured":"Boyd AT, Oboho I, Paulin H, Ali H, Godfrey C, Date A, et al. Addressing advanced HIV disease and mortality in global HIV programming. AIDS Res Ther. 2020;17:40.","journal-title":"AIDS Res Ther"},{"key":"14021_CR10","unstructured":"World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: WHO. 2017. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241550062"},{"key":"14021_CR11","doi-asserted-by":"publisher","first-page":"e0230453","DOI":"10.1371\/journal.pone.0230453","volume":"15","author":"Z Ndlovu","year":"2020","unstructured":"Ndlovu Z, Massaquoi L, Bangwen NE, Batumba JN, Bora RU, Mbuaya J, et al. Diagnostic performance and usability of the VISITECT CD4 semi-quantitative test for advanced HIV disease screening. PLoS ONE. 2020;15:e0230453.","journal-title":"PLoS ONE"},{"key":"14021_CR12","unstructured":"Ministry of Health Uganda. Consolidated guidelines for the prevention and treatment of HIV and AIDS in Uganda. 2020. Kampala; 2020."},{"key":"14021_CR13","unstructured":"WHO Africa. BD FACSPresto Near-Patient CD4 Counter. 2020. Available from: https:\/\/innov.afro.who.int\/emerging-technological-innovations\/bd-facspresto-near-patient-cd4-counter-with-bd-cd4-cd4-hb-cartridge-and-bd-facspresto-cartridges-kit-3599"},{"key":"14021_CR14","unstructured":"Abbott. Pima Analyser. 2023. Available from: https:\/\/www.globalpointofcare.abbott\/en\/product-details\/pima-analyser-ous.html"},{"key":"14021_CR15","doi-asserted-by":"publisher","first-page":"e0226987","DOI":"10.1371\/journal.pone.0226987","volume":"15","author":"K Lamp","year":"2020","unstructured":"Lamp K, McGovern S, Fong Y, Atem CD, Nfetam JBE, Nzuobontane D, et al. Proportions of CD4 test results indicating advanced HIV disease remain consistently high at primary health care facilities across four high HIV burden countries. PLoS ONE. 2020;15:e0226987.","journal-title":"PLoS ONE"},{"key":"14021_CR16","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1097\/QAI.0b013e3182928f27","volume":"63","author":"BM Morawski","year":"2013","unstructured":"Morawski BM, Meya DB, Boulware DR. Accuracy of Pima point-of-care CD4 analyzer in routine use in public health clinics in Uganda. J Acquir Immune Defic Syndr. 2013;63:e113\u20135.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"14021_CR17","doi-asserted-by":"publisher","first-page":"e1002088","DOI":"10.1371\/journal.pmed.1002088","volume":"13","author":"V Habiyambere","year":"2016","unstructured":"Habiyambere V, Ford N, Low-Beer D, Nkengasong J, Sands A, Gonz\u00e1lez MP, et al. Availability and use of HIV monitoring and early infant diagnosis technologies in WHO member states in 2011\u20132013: analysis of annual surveys at the facility level. PLoS Med. 2016;13:e1002088.","journal-title":"PLoS Med"},{"key":"14021_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/COH.0000000000000351","volume":"12","author":"PK Drain","year":"2017","unstructured":"Drain PK, Rousseau C. Point-of-care diagnostics: extending the laboratory network to reach the last mile. Curr Opin HIV AIDS. 2017;12:175\u201381.","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"14021_CR19","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1097\/QAI.0b013e3182928f27","volume":"63","author":"BM Morawski","year":"2013","unstructured":"Morawski BM, Meya DB, Boulware DR. Accuracy of Pima point-of-care CD4 analyzer in routine use in public health clinics in Uganda. J Acquir Immune Defic Syndr. 2013;63(3):e113\u20135. https:\/\/doi.org\/10.1097\/QAI.0b013e3182928f27.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"14021_CR20","unstructured":"Abbott. Pima Analyser [package insert]. Chicago: Abbott; 2023. Available from: https:\/\/www.globalpointofcare.abbott\/en\/product-details\/pima-analyser-ous.html"},{"key":"14021_CR21","unstructured":"Abbott. Alere Pima CD4 Analyser [technical documentation]. 2022. Available from: https:\/\/pdf.medicalexpo.com\/pdf\/abbott\/alere-pima-cd4-analyser\/67555-116273.html"},{"key":"14021_CR22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1186\/1756-0500-5-563","volume":"5","author":"TGK Bentley","year":"2012","unstructured":"Bentley TGK, Catanzaro A, Ganiats TG. Implications of the impact of prevalence on test thresholds and outcomes: lessons from tuberculosis. BMC Res Notes. 2012;5:563. https:\/\/doi.org\/10.1186\/1756-0500-5-563. PubMed PMID: 23050607.","journal-title":"BMC Res Notes"},{"issue":"3","key":"14021_CR23","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1097\/QAI.0b013e3182928f27","volume":"63","author":"BM Morawski","year":"2013","unstructured":"Morawski BM, Meya DB, Boulware DR. Accuracy of Pima point-of-care CD4 analyzer in routine use in public health clinics in Uganda. J Acquir Immune Defic Syndr. 2013;63(3):e113\u20135. https:\/\/doi.org\/10.1097\/QAI.0b013e3182928f27. PubMed PMID: 23760094.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"14021_CR24","doi-asserted-by":"publisher","first-page":"e88928","DOI":"10.1371\/journal.pone.0088928","volume":"9","author":"RM Galiwango","year":"2014","unstructured":"Galiwango RM, Lubyayi L, Musoke R, Kalibbala S, Buwembo M, Kasule J, et al. Field evaluation of PIMA point-of-care CD4 testing in Rakai, Uganda. PLoS ONE. 2014;9(3):e88928. https:\/\/doi.org\/10.1371\/journal.pone.0088928. PubMed PMID: 24614083.","journal-title":"PLoS ONE"},{"key":"14021_CR25","unstructured":"World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: WHO. 2017. ISBN: 9789241550062."},{"issue":"3","key":"14021_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1615822","volume":"377","author":"J Hakim","year":"2017","unstructured":"Hakim J, Musiime V, Szubert AJ, Siika A, Mallewa J, Agutu C, et al. REALITY Trial Team. Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa. N Engl J Med. 2017;377(3):233\u201345. doi: 10.1056\/NEJMoa1615822. PubMed PMID: 28723333.","journal-title":"N Engl J Med"},{"issue":"9983","key":"14021_CR27","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/S0140-6736(15)60164-7","volume":"385","author":"S Mfinanga","year":"2015","unstructured":"Mfinanga S, Chanda D, Kivuyo SL, Guinness L, Bottomley C, Simms V, et al. REMSTART trial team. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet. 2015;385(9983):2173\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(15)60164-7. PubMed PMID: 25765698.","journal-title":"Lancet"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-14021-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14021-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14021-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:53:09Z","timestamp":1792536789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-14021-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14021"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-14021-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"26 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Makerere University School of Biomedical Sciences Research Ethics Committee (Approval number: SBS-2023-441). All participants provided informed consent prior to their involvement in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (no individual person\u2019s data in any form is presented).","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1850"}}